Clinical trial protocols of repurposed prophylaxis for COVID-19: A review (France 2020-10-03) Barely worth briefing, out-of-date and too-brief about ivermectin

TrumpLyftAlles | 1 points | Dec 13 2020 01:43:34

Clinical trial protocols of repurposed prophylaxis for COVID-19: A review (France 2020-10-03) Barely worth briefing, out-of-date and too-brief about ivermectin

https://www.sciencedirect.com/science/article/pii/S0399077X20307113

[-] TrumpLyftAlles | 1 points | Dec 13 2020 01:43:44

4.11. Ivermectin Ivermectin is an FDA-approved broad spectrum anti-parasitic and anti-viral agent. It was shown to inhibit SARS-CoV-2 replication in vitro [37]. However, the concentrations necessary to achieve inhibition in this study cannot be reached in patients’ blood without serious side effects [38]. Ivermectin is however investigated in the phase 3 clinical trials NCT04446104 and 2020-001994-66 at doses of 12 mg/day, which is significantly higher than the doses used against parasites (of the order of 100 mg every few months).